Neuronetics (NASDAQ:STIM) Stock Rating Lowered by Wall Street Zen

Neuronetics (NASDAQ:STIM) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other research analysts have also issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, January 22nd. Canaccord Genuity Group cut their target price on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.00.

Neuronetics Stock Down 4.3%

NASDAQ:STIM opened at $1.45 on Friday. Neuronetics has a twelve month low of $0.80 and a twelve month high of $5.05. The firm has a market capitalization of $100.45 million, a price-to-earnings ratio of -2.46 and a beta of 0.87. The company has a quick ratio of 2.09, a current ratio of 2.02 and a debt-to-equity ratio of 2.51. The stock’s 50 day moving average price is $1.60 and its two-hundred day moving average price is $2.03.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company had revenue of $41.78 million during the quarter, compared to the consensus estimate of $40.84 million. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%. Equities research analysts expect that Neuronetics will post -1.13 earnings per share for the current fiscal year.

Insider Transactions at Neuronetics

In other Neuronetics news, major shareholder Jorey Chernett acquired 607,400 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was acquired at an average price of $1.35 per share, for a total transaction of $819,990.00. Following the purchase, the insider directly owned 8,123,804 shares of the company’s stock, valued at $10,967,135.40. This trade represents a 8.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Keith J. Sullivan sold 40,976 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $1.55, for a total transaction of $63,512.80. Following the completion of the sale, the chief executive officer directly owned 1,567,012 shares of the company’s stock, valued at $2,428,868.60. This represents a 2.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 1,588,400 shares of company stock worth $2,034,450 and have sold 104,307 shares worth $164,097. 8.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neuronetics

Large investors have recently added to or reduced their stakes in the stock. Madryn Asset Management LP bought a new position in Neuronetics during the 4th quarter worth $25,497,000. Vanguard Group Inc. lifted its position in shares of Neuronetics by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company’s stock valued at $7,732,000 after acquiring an additional 89,504 shares during the period. UBS Group AG lifted its position in shares of Neuronetics by 20.4% during the 4th quarter. UBS Group AG now owns 2,607,047 shares of the company’s stock valued at $3,598,000 after acquiring an additional 442,216 shares during the period. Lane Generational LLC acquired a new stake in shares of Neuronetics during the 4th quarter worth $2,353,000. Finally, Balyasny Asset Management L.P. grew its holdings in shares of Neuronetics by 6.5% during the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company’s stock worth $5,267,000 after purchasing an additional 92,048 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Key Headlines Impacting Neuronetics

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
• Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
• Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
• Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.